TY - JOUR
T1 - Modulating fatty acid metabolism and the AMP-activated protein kinase pathway as a target for obesity therapy
AU - Kim, Eun Kyoung
AU - Landree, Leslie E.
AU - Kuhajda, Francis P.
AU - Ronnett, Gabriele V.
PY - 2005/10
Y1 - 2005/10
N2 - Obesity and its attendant disorders, such as Type 2 diabetes, have reached epidemic proportions globally. Despite significant advances in the understanding of appetite and satiety at molecular levels, practical therapies for weight loss remain a daunting problem. An approach that we have utilized is to identify pathways that alter cellular energy flux as a means to manipulate central and peripheral energy sensing. These studies indicate that several enzymes within metabolic pathways that regulate fatty acid metabolism may serve as targets for pharmacological interventions for obesity. We review studies that support the use of modulators of fatty acid synthase (FAS) and carnitine palmitoyltransferase-1 (CPT-1) to influence known energy sensors such as AMP-activated protein kinase (AMPK) to affect food intake and energy consumption. Substantial work in the past several years herein reviewed has centered on characterizing the effects of C75, a synthetic FAS inhibitor and CPT-1 stimulator, on feeding behavior and energy consumption. The collective effect of C75 is to cause profound anorexia and reversible weight loss beyond that accounted for by decreased food intake. In addition to physiological studies, mechanistic cellular and molecular studies have provided insight into mediators responsible for the anorexia. C75 increases ATP levels in many cell types, including neurons, to signal a favorable energy balance, which in turn inhibits hypothalamic AMPK, and alters gene expression in neurons and in peripheral tissues, further supporting weight loss. Compounds have been developed that selectively inhibit FAS and that selectively stimulate CPT-1 to permit further explorations into the contributions of these two pathways to energy sensing. Recent studies indicate that modulation of FAS/CPT-1 activities can affect a number of cellular processes, depending on cell type and physiological context, and thus these compounds may have implications for treating other CNS disorder as well.
AB - Obesity and its attendant disorders, such as Type 2 diabetes, have reached epidemic proportions globally. Despite significant advances in the understanding of appetite and satiety at molecular levels, practical therapies for weight loss remain a daunting problem. An approach that we have utilized is to identify pathways that alter cellular energy flux as a means to manipulate central and peripheral energy sensing. These studies indicate that several enzymes within metabolic pathways that regulate fatty acid metabolism may serve as targets for pharmacological interventions for obesity. We review studies that support the use of modulators of fatty acid synthase (FAS) and carnitine palmitoyltransferase-1 (CPT-1) to influence known energy sensors such as AMP-activated protein kinase (AMPK) to affect food intake and energy consumption. Substantial work in the past several years herein reviewed has centered on characterizing the effects of C75, a synthetic FAS inhibitor and CPT-1 stimulator, on feeding behavior and energy consumption. The collective effect of C75 is to cause profound anorexia and reversible weight loss beyond that accounted for by decreased food intake. In addition to physiological studies, mechanistic cellular and molecular studies have provided insight into mediators responsible for the anorexia. C75 increases ATP levels in many cell types, including neurons, to signal a favorable energy balance, which in turn inhibits hypothalamic AMPK, and alters gene expression in neurons and in peripheral tissues, further supporting weight loss. Compounds have been developed that selectively inhibit FAS and that selectively stimulate CPT-1 to permit further explorations into the contributions of these two pathways to energy sensing. Recent studies indicate that modulation of FAS/CPT-1 activities can affect a number of cellular processes, depending on cell type and physiological context, and thus these compounds may have implications for treating other CNS disorder as well.
KW - AMPK
KW - C75
KW - CPT-1
KW - Fatty acid synthase (FAS)
KW - Food intake
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=24944435092&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=24944435092&partnerID=8YFLogxK
U2 - 10.2174/156801305774322402
DO - 10.2174/156801305774322402
M3 - Article
AN - SCOPUS:24944435092
SN - 1568-0134
VL - 5
SP - 439
EP - 450
JO - Current Medicinal Chemistry: Immunology, Endocrine and Metabolic Agents
JF - Current Medicinal Chemistry: Immunology, Endocrine and Metabolic Agents
IS - 5
ER -